Uses of Upadacitinib

What is Upadacitinib? Upadacitinib is the main ingredient of the drug with the brand name Rinvoq 15mg, which is made in the form of slow-release tablets.
Mechanism of action:
Janus kinase (JAK) is an intracellular enzyme that transmits signals arising from interactions between cytokines or growth factors and receptors on the cell membrane, thereby affecting cell membrane metabolism. hematopoiesis and immune cell function. In addition, JAKs have a Phosphorylation effect, while activating signal transduction and transcriptional activators (STATs) that regulate intracellular activity including gene expression.
Upadacitinib is a Janus kinase (JAK) inhibitor, which inhibits Phosphorylation and transcriptional activation (STATs). The result of this process is inhibition of blood cell production and reduced function of immune cells, which in turn reduces inflammation and helps control symptoms of the inflammatory process.

Upadacitinib is indicated for the treatment of the following:
Adults with moderate to severe rheumatoid arthritis who have not responded to a variety of tumor necrosis factor (TNF) inhibitors. Adults with active psoriatic arthritis not responding to a variety of tumor necrosis factor (TNF) inhibitors. Adults or children over 12 years old or over 40 kg with moderate to severe eczema (atopic dermatitis) that has not responded to previous treatment. Adults with moderate to severe ulcerative colitis who have not responded to one or more tumor necrosis factor (TNF) inhibitors.

Contraindicated to use Upadacitinib in the following cases:
Hypersensitivity to any ingredient of the drug. History of allergy to other drugs containing Upadacitinib. Patient has TB infection or severe infection. Pregnant women. Patients with severe hepatic impairment (Child-Pugh C). Children under 12 years old.

Patients can take Upadacitinib before, during and after meals.
Rheumatoid arthritis
Recommended dose: 15 mg/time x 1 time/day. Recommendation
May be used as a single dose or in combination with Methotrexate or DMARDs. The use of Upadacitinib is not recommended in patients with an absolute lymphocyte count (ALC) < 500 cells/mm3, an absolute neutrophil count (ANC) < 1000 cells/mm3, or a hemoglobin level < 8 g/mm. dL. Discontinue treatment with Upadacitinib when the patient has a severe infection until the infection is under control.

Treatment with Upadacitinib in high doses or for a long time, can cause the side effects listed in the following table:

Should stop the drug when detecting the above symptoms or other abnormalities after taking Upadacitinib and promptly inform the treating doctor about the use of Upadacitinib or immediately go to the nearest medical facility for timely treatment. time.
Note the use of Upadacitinib in the following subjects:
Use caution when using Upadacitinib in people with a history of or ongoing infections, or recurrent infections, diabetes, chronic obstructive pulmonary disease (COPD). COPD ), HIV or a weakened immune system, tuberculosis, or close contact with someone with tuberculosis, shingles (Herpes zoster), hepatitis B or C. Pregnant women: Limited human data It is not sufficient to assess the risk of birth defects or miscarriage in pregnant women receiving Upadacitinib. Therefore, the use of Upadacitinib is contraindicated in women who are pregnant or intend to become pregnant. Lactation: Studies have shown that the active ingredient Upadacitinib can pass into breast milk, however, the effects of Upadacitinib on breastfed infants are not well understood. Therefore, breast-feeding is not recommended while taking Upadacitinib and for 6 days after the last dose. Drivers or machine operators may experience some side effects such as headache and fatigue after using Upadacitinib. Therefore, it is not recommended to take Upadacitinib before and during work.

Interactions with other drugs:
CYP3A4 inhibitors used to treat fungi such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole and Clarithromycin for bacterial infections may increase blood levels of Upadacitinib. Strong CYP3A4 inducers such as Rifampin and Phenytoin may reduce the effect of Upadacitinib. Azathioprine and Cyclosporine may increase the risk of infection when used together with Upadacitinib. Methotrexate and pH regulators such as antacids or proton pump inhibitors do not affect blood levels of Upadacitinib. Above is the necessary information about the ingredients, uses, doses and side effects or notes of Upadacitinib. Patients and family members should be carefully instructed on the package of Upadacitinib, and consult the treating doctor before deciding to use.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.